Mercer Global Advisors
BTAI icon

Mercer Global Advisors’s BioXcel Therapeutics BTAI Stock Holding History

Mercer Global Advisors’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45 Buy
+32
New +$37 ﹤0.01% 6011

Other funds holding BTAI

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $1.02B AUM 45.95% 1-Year Est. Return
DAS
Diversify Advisory Services Sandy, Utah $5.98B AUM 28.55% 1-Year Est. Return
DWM
Diversify Wealth Management Sandy, Utah $5.98B AUM 29.21% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Mercer Global Advisors's BTAI Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 32 shares worth $45. The stake represents ﹤0.01% of the portfolio and ranks #6011 among its holdings.

18 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Mercer Global Advisors held 32 shares of BioXcel Therapeutics worth $45 as of Q2 2026.
  • BioXcel Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #6011 holding.
  • 18 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.